CHEK1 and head and neck squamous cell carcinoma: Based on our study and data of others60, a phase I/II clinical trial with a highly specific Chk1 inhibitor with or without cell cycle enhancing therapy such as Wee1 inhibition may be initiated for recurrent/metastatic HNSCC.